Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 3
1995 1
2010 1
2011 2
2013 1
2017 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
[Pharmacokinetic interactions of telaprevir with other drugs].
Berenguer Berenguer J, González-García J. Berenguer Berenguer J, et al. Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:37-48. doi: 10.1016/S0213-005X(13)70123-X. Enferm Infecc Microbiol Clin. 2013. PMID: 24063902 Review. Spanish.
Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ. Moreno Guillen S, et al. Among authors: berenguer berenguer j. Farm Hosp. 2017 Sep 1;41(5):601-610. doi: 10.7399/fh.10808. Farm Hosp. 2017. PMID: 28847249 English.
The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients.
López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, Tural C, Hernando A, González-García J, Serrano L, Arribas JR; GESIDA 37/03-FIPSE 36465/03-NEAT IG5 Study Group. López-Diéguez M, et al. AIDS. 2011 Apr 24;25(7):899-904. doi: 10.1097/QAD.0b013e3283454174. AIDS. 2011. PMID: 21330908
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY; QDMRK Investigators. Eron JJ Jr, et al. Lancet Infect Dis. 2011 Dec;11(12):907-15. doi: 10.1016/S1473-3099(11)70196-7. Epub 2011 Sep 18. Lancet Infect Dis. 2011. PMID: 21933752 Clinical Trial.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Molina JM, et al. Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. Lancet HIV. 2020. PMID: 31740348 Clinical Trial.